Thanks TOB. My thoughts concur with your post. With so much positive news on a broad scale and we can't get back to $2.00, let alone $2.50....what's wrong ?
Anyone else with this much in the works, even on OTC, would have a higher valuation, in my view.
This surprises me, really. Just based upon the advancement of the Kevetrin trial at the Harvard Cancer Centers which by all reports is going fantastic, and a nearly a sure win considering the dosage being in the range considered likely efficacious and the lack of dose limiting toxicities to date.
Factor in the new phase 2b clinical trial underway for Brilacidin, the other Kevetrin combination clinical trial getting ready to start, and the IND for Prurisol... well it doesn't make much sense that CTIX has yet to make new highs.
I expected higher valuations, sooner. But... we need new buyers for that, and CTIX is not yet off the OTCQB
Market Data 
Markets 
AI
